Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory syncytial virus (RSV) vaccine in children.
Codagenix has dosed the first subject in a Phase I study (NCT04919109) designed to test the safety and immunogenicity of CodaVax-RSV, the company announced Wednesday. The trial will vaccinate 51 healthy children in the spring to early autumn of 2023 and follow participants through the 2023–2024 RSV season.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase I study will test CodaVax-RSV or placebo in 18 children aged 2–5 followed by 33 children aged 6 months to 2 years. Primary outcomes focus on safety, while the secondary endpoint explores neutralising antibody levels.
CodaVax-RSV, which has US Food and Drug Administration (FDA) fast track designation, is part of Codagenix’s live-attenuated vaccine platform that also targets Covid-19 and influenza. Codagenix also plans to initiate a Phase II trial of the same vaccine during the 2023-2024 RSV season.
As Codagenix begins dosing in its new Phase I trial, the race to develop RSV vaccines is quickly heating up. New investment and a recent uptick in pediatric and elderly RSV cases has placed a renewed spotlight on the respiratory virus.
Correction: A previous version of this article incorrectly stated that CodaVax-RSV is an mRNA-based vaccine. The headline and article have been updated to reflect that it is a live-attenuated vaccine.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
